Search Within

Josiah David Land

Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Clinical Pharmacy Specialists (7)
  2. Department of Medicine (6)
  3. Biostatistics Service (5)
  4. Epidemiology and Biostatistics (5)
  5. Solid Tumor Oncology Division (5)
  6. Thoracic Oncology (5)

More Groups

People
  1. Dazhi Liu (5)
  2. Gregory Riely (5)
  3. Larry Buie (5)
  4. Terry Pak (5)
  5. Alexander Drilon (4)
  6. Bob Li (4)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2019 (2)
  4. 2018 (1)
  5. 2017 (1)
  6. 2015 (1)
Publications
  1. Blood (1)
  2. British Journal of Cancer (1)
  3. JCO Precision Oncology (1)
  4. Journal of Clinical Oncology (1)
  5. Journal of Oncology Pharmacy Practice (1)
  6. Journal of Thoracic Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. American Society of Hematology (1)
  3. Elsevier Inc. (1)
  4. Nature Publishing Group (1)
  5. Oxford University Press (1)
  6. Sage Publications Ltd. (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers
    Journal Article

    Murciano-Goroff, Y. R.; Pak, T.; Mondaca, S.; Flynn, J. R.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Plodkowski, A. J.; Wu, S. L.; Kris, M. G.; more...
    British Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City
    Journal Article

    Yerram, P.; Thackray, J.; Modelevsky, L. R.; Land, J. D.; Reiss, S. N.; Spatz, K. H.; Levoir, A. C.; Pak, T. K.; Dao, P. H.; Buege, M. J.; more...
    Journal of Oncology Pharmacy Practice (2021)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
    Journal Article

    Offin, M.; Guo, R.; Wu, S. L.; Sabari, J.; Land, J. D.; Ni, A.; Montecalvo, J.; Halpenny, D. F.; Buie, L. W.; Pak, T.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • RET-rearranged lung cancers: Immunophenotype and response to immunotherapy
    Meeting Abstract

    Sabari, J. K.; Offin, M. D.; Wu, S. L.; Ni, A.; Halpenny, D.; Montecalvo, J.; Liu, D.; Pak, T. K.; Arbour, K. C.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prognostic factors and outcomes of patients with central nervous system (CNS) metastatic ALK-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kachur, E.; Reiss, S.; Land, J.; Buie, L.; Reiner, A.; Panageas, K.; Riely, G.; Pentsova, E.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Incidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Land, J.; Afifi, S.; Adel, N. G.; Devlin, S.; Arora, A.; Lendvai, N.; Landgren, O.
    Blood (2015)

    Fulltext@MSK | Save